摘要
肥胖的患病率逐年升高,是众多慢性病的潜在危险因素。然而,肥胖治疗面临药物选择少、副作用多等问题。生长抑素(SST)在摄食及食欲调节中发挥重要作用。越来越多的证据表明,SST通过影响饱腹感及摄食行为,在肥胖的管理中具有潜在的临床应用价值。SST可与胰岛素、刺鼠相关肽、阿黑皮素原、瘦素、胃饥饿素和脑源性神经营养因子等形成广泛的调节网络,有效调控肥胖及其相关疾病的发生和发展。SST在减重中的作用及机制的深入研究,将为治疗肥胖的新型药物研发开辟新的视角。另外,考虑到天然激素的局限性,SST类似物是治疗肥胖的良好候选药物,有望广泛研发以应用于临床。本文亦根据目前存在的问题,提出未来具体的研究方向,旨在为肥胖治疗提供相关科学依据。
The prevalence of obesity is increasing year by year,and obesity is a potential risk factor for many chronic diseases.However,obesity treatment faces problems such as few drug options and many side effects.Somatostatin(SST)plays an important role in food intake and appetite regulation.More and more evidence suggests that SST has potential value of clinical application in the management of obesity by affecting satiety and feeding behavior.SST can effectively regulate the occurrence and development of obesity and its related diseases by forming a wide regulatory network with insulin,agouti-related peptide,proopiomelanocortin,leptin,ghrelin,and brain-derived neurotrophic factor.The in-depth study of the role and mechanism of SST in weight loss will open up a new perspective for the development of new drugs for the treatment of obesity.In addition,considering the limitations of natural hormones,SST analogs are good candidates for the treatment of obesity and are expected to be widely developed for clinical application.According to the existing problems,this paper also proposes specific research directions in the future,aiming at providing relevant scientific basis for the treatment of obesity.
作者
孙烁烁
韦晓
张少红
刘超
SUN Shuoshuo;WEI Xiao;ZHANG Shaohong;LIU Chao(Department of Endocrinology,Affiliated Hospital of Integrated Traditional Chinese and Western Medicine,Nanjing University of Chinese Medicine,Jiangsu Province,Nanjing210028,China;Department of Geriatrics,the Affiliated Huaian NO.1 People’s Hospital of Nanjing Medical University,Jiangsu Province,Huaian223300,China)
出处
《中国医药导报》
CAS
2023年第15期53-56,共4页
China Medical Herald
基金
江苏省中医药领军人才培养项目(SLJ0209)。
